Omilancor

Omilancor (BT-11) is an experimental drug which acts as an activator of the protein Lanthionine Synthetase C-like 2 (LANCL2). It has antiinflammatory effects and shows efficacy against psoriasis as well as inflammatory bowel conditions, and is in clinical trials for the treatment of Crohn's disease and ulcerative colitis.^[1][2][3] It also shows affinity for the enzyme MAP2K6 and may have potential application in the treatment of intervertebral disc degeneration.^[4]

Omilancor

Identifiers
IUPAC name [4-[6-(1H-benzimidazol-2-yl)pyridine-2-carbonyl]piperazin-1-yl]-[6-(1H-benzimidazol-2-yl)pyridin-2-yl]methanone
CAS Number	1912399-75-7
PubChem CID	121299620
IUPHAR/BPS	10363
DrugBank	DB19277
ChemSpider	64907766
UNII	A4Y49H6YY8
ChEMBL	ChEMBL4788758
Chemical and physical data
Formula	C30H24N8O2
Molar mass	528.576 g·mol−1
3D model (JSmol)	Interactive image
SMILES C1CN(CCN1C(=O)C2=CC=CC(=N2)C3=NC4=CC=CC=C4N3)C(=O)C5=CC=CC(=N5)C6=NC7=CC=CC=C7N6
InChI InChI=1S/C30H24N8O2/c39-29(25-13-5-11-23(31-25)27-33-19-7-1-2-8-20(19)34-27)37-15-17-38(18-16-37)30(40)26-14-6-12-24(32-26)28-35-21-9-3-4-10-22(21)36-28/h1-14H,15-18H2,(H,33,34)(H,35,36) Key:MVHWZNBAQIGPOQ-UHFFFAOYSA-N